Rxsight Inc
NASDAQ:RXST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rxsight Inc
NASDAQ:RXST
|
US |
|
Talanx AG
LSE:0QA8
|
DE |
|
A
|
Axis Bank Ltd
LSE:AXB
|
IN |
|
ICICI Bank Ltd
NSE:ICICIBANK
|
IN |
|
J
|
Johnson Controls International PLC
LSE:0Y7S
|
IE |
|
F
|
Fiserv Inc
SWB:FIV
|
US |
|
S
|
Stroeer SE & Co KgaA
XHAM:SAX
|
DE |
|
Talanx AG
OTC:TNXXF
|
DE |
|
T
|
Technogym SpA
XBER:TN2
|
IT |
|
Broadstone Net Lease Inc
NYSE:BNL
|
US |
|
Ross Stores Inc
NASDAQ:ROST
|
US |
|
B
|
Berry Global Group Inc
F:BP0
|
US |
|
Volkswagen AG
XETRA:VOW
|
DE |
|
CK Asset Holdings Ltd
OTC:CNGKY
|
HK |
Rxsight Inc
RxSight makes a cataract treatment system built around the Light Adjustable Lens, an intraocular lens that can be fine-tuned after surgery with a special light treatment. In simple terms, it helps eye surgeons correct a patient’s vision after the lens has already been implanted, which can improve the chance of a precise result. The company sells the lens itself and the equipment doctors use to adjust it, along with related services and supplies. Its main customers are ophthalmologists, cataract surgery centers, and hospitals that perform lens replacement procedures. RxSight makes money when those providers buy the lenses, the light-based treatment system, and the ongoing consumables needed to use the platform. What makes RxSight different is that it sells a cataract lens system rather than a general-purpose medical device. Its business sits in the eye-surgery supply chain as a specialized tool for surgeons who want more control over the final vision outcome. That gives the company a focused role in cataract care, where precision and repeat procedure use matter.
RxSight makes a cataract treatment system built around the Light Adjustable Lens, an intraocular lens that can be fine-tuned after surgery with a special light treatment. In simple terms, it helps eye surgeons correct a patient’s vision after the lens has already been implanted, which can improve the chance of a precise result.
The company sells the lens itself and the equipment doctors use to adjust it, along with related services and supplies. Its main customers are ophthalmologists, cataract surgery centers, and hospitals that perform lens replacement procedures. RxSight makes money when those providers buy the lenses, the light-based treatment system, and the ongoing consumables needed to use the platform.
What makes RxSight different is that it sells a cataract lens system rather than a general-purpose medical device. Its business sits in the eye-surgery supply chain as a specialized tool for surgeons who want more control over the final vision outcome. That gives the company a focused role in cataract care, where precision and repeat procedure use matter.
Revenue hit: RxSight said preliminary Q2 total revenue should be about $32 million to $34 million, but sales excluding the Alcon collaboration were about $27 million, down 20% year over year.
Guidance reset: Full-year 2026 revenue guidance was cut to $140 million to $160 million, reflecting softer core RxSight sales and $30 million to $40 million of collaboration revenue.
Margins improved: Gross margin guidance was raised to 73% to 75% from 70% to 72%, helped by a better mix of LALs versus LDDs.
Competitive pressure: Management blamed weaker utilization partly on competitive trialing tied to new premium lens launches and said the tougher environment should last through year-end.
Strategic shift: RxSight highlighted both its Alcon partnership and its internal next-generation adjustable lens pipeline as long-term growth drivers.
Commercial response: The company is increasing U.S. sales force investment and reengagement efforts to defend and deepen adoption at existing accounts.
